

## Abbott Laboratories

[View the current Abbott Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/17656-Abbott+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/17656-Abbott+Laboratories.html>)

### Contact Details:

**100 Abbott Park Road**

**Abbott Park**

**Illinois**

**60064-3500**

**United States of America**

Tel: (847) 937-6100

Fax:

Email: [webmaster@abbott.com](mailto:webmaster@abbott.com)

We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself – addressing important health needs from infancy to the golden years.

Throughout our 100+ year history, Abbott people have been driven by a constant goal: to advance medical science to help people live healthier lives. It's part of our heritage. And, it continues to drive our work. Today, 65,000 Abbott employees around the world share the passion for "Turning Science Into Caring." It's a commitment to focusing on what matters most: life and the potential it holds when we are feeling our best. Abbott has sales, manufacturing, research and development, and distribution facilities around the world, close to where our customers need us to be. We are recognized for our global reach and our ability to serve our customers around the world.

Abbott prides itself on being recognized as a good place to work because we strive to provide an environment that enables employees to succeed. We have received numerous local, national and international distinctions for our commitment to workplace excellence. Our programs range from award-winning health care benefits to a variety of convenience and wellness services and long-term retirement benefits.

Our commitment to improving life extends to humanitarian causes. We recognize that as a leading provider of innovative health care products, we have a unique responsibility and opportunity to ensure people have access to them – whether they are among the poor and underprivileged or are victims of natural disasters.

We're determined to do our part through creative and varied social programs.

The promise of our company is in the promise that our work holds for health and for life

**Recent Publications by Abbott Laboratories:**



- [ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.](#)  
*ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic...* 13th November, 2008  
Global Pharmaceutical Research and Development, Abbott Laboratories,- Mol Cancer Ther. 2008 Oct;7(10):3265-74. ([DOI Direct Link](#))
- [Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development.](#)  
*Hepatotoxicity is a common cause of failure in drug discovery and...* 11th November, 2008  
Department of Cellular, Molecular and Exploratory Toxicology, Global- Toxicol Lett. 2008 Oct 17. ([DOI Direct Link](#))
- [Behavioral profile of P2X\(7\) receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders.](#)  
*The purinergic P2X(7) receptor is a ligand-gated ion channel found on...* 11th November, 2008  
Neuroscience Research, Global Pharmaceutical Research and Development,- Behav Brain Res. 2008 Oct 18. ([DOI Direct Link](#))
- [Thermodynamics, Molecular Mobility and Crystallization Kinetics of Amorphous Griseofulvin.](#)  
*Griseofulvin is a small rigid molecule that shows relatively high...* 7th November, 2008  
Global Pharmaceutical R&D, and Global Pharmaceutical Operations, Abbott- Mol Pharm. 2008 Nov 6. ([DOI Direct Link](#))
- [Potentiation of temozolomide cytotoxicity by poly\(ADP\)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.](#)  
*Poly(ADP-ribose) polymerase (PARP) senses DNA breaks and facilitates DNA...* 6th November, 2008  
Cancer Research, GPRD, Abbott Laboratories, Abbott Park, IL, USA.- Mol Cancer Res. 2008 Oct;6(10):1621-9. ([DOI Direct Link](#))
- [Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma.](#)  
*PURPOSE: Sarcomas are among the most proangiogenic malignancies in...* 5th November, 2008  
University of Michigan Medical School, Ann Arbor, MI; Cancer Therapy and- J Clin Oncol. 2008 Nov 3. ([DOI Direct Link](#))
- [Cloning and characterization of the monkey histamine H\(3\) receptor isoforms.](#)  
*We have recently identified five splice isoforms of the histamine H(3)...* 4th November, 2008  
Neuroscience Research, Global Pharmaceutical Research Division, Abbott- Eur J Pharmacol. 2008 Oct 21. ([DOI Direct Link](#))
- [In search of negative allosteric modulators of biological targets.](#)  
*The value of using negative allosteric modulators of protein function in...* 1st November, 2008  
Abbott Laboratories, R4PN/J35, 200 Abbott Park Road, Abbott Park, IL- Drug Discov Today. 2008 Oct 27. ([DOI Direct Link](#))
- [Psoriasis Area and Severity Index: Nuts and bolts of measuring disease severity in psoriasis.](#)  
*The value of using negative allosteric modulators of protein function in...* 23rd October, 2008  
Immunology Development, Abbott Laboratories, Abbott Park, IL 60064-6149,- Clin Dermatol. 2008 Nov-Dec;26(6):653-6. ([DOI Direct Link](#))
- [Characterization of a Cannabinoid CB2 Receptor Selective Agonist, A-836339, in In Vitro Pharmacological assays and In Vivo Pain Models.](#)  
*Studies demonstrating the anti-hyperalgesic and anti-allodynic effects of...* 22nd October, 2008  
Abbott Laboratories.- J Pharmacol Exp Ther. 2008 Oct 17. ([DOI Direct Link](#))
- [Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt.](#)  
*In previously reported applications of salting-out assisted liquid/liquid...* 18th October, 2008  
Department of Drug Analysis, Abbott Laboratories, 100 Abbott Park Road,- J Pharm Biomed Anal. 2008 Sep 9. ([DOI Direct Link](#))
- [Success is not necessarily automatic.](#)  
*There are a number of factors (planning, process optimization,...)* 18th October, 2008  
Pharmaceutical and Analytical Research and Development Abbott Laboratories- J Automat Chem. 1998;20(4):109-10. ([DOI Direct Link](#))

- [A fully automated liquid-liquid extraction system utilizing interface detection.](#)  
*The development of the Abbott Liquid-Liquid Extraction Station was a...*18th October, 2008  
Abbott Laboratories Abbott Park IL USA.- J Autom Methods Manag Chem. 2000;22(6):187-94. ([DOI Direct Link](#))
- [Comparison of cardiovascular effects in conscious and pentobarbital anesthetized dogs.](#)  
*ABT-263 is a potent, orally bioavailable inhibitor of the antiapoptotic...*14th October, 2008  
Abbott Laboratories, Abbott Park, IL, 60064, USA.- J Pharmacol Toxicol Methods. 2008 September - October;58(2):148. ([DOI Direct Link](#))
- [Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.](#)  
*Overexpression of prosurvival proteins such as Bcl-2 and Bcl-X L has been...*10th October, 2008  
Cancer Research, Global Pharmaceutical Research and Development, Abbott- J Med Chem. 2008 Nov 13;51(21):6902-15. Epub 2008 Oct 8. ([DOI Direct Link](#))

## BioNews Results for Abbott Laboratories



- [Abbott's TriLipix improves cholesterol long term](#)  
*QualityHealth.com: Nov 16 2008 5:42PM Matching: abbott laboratories*
- [Learn about the Forensic Technologies: New and Growing Markets](#)  
*SmartBrief: Nov 14 2008 1:38PM Matching: abbott laboratories*
- [Exploring Solid-State Chemistry](#)  
*Pharmaceutical Technology: Nov 14 2008 11:22PM Matching: abbott laboratories*
- [TyRx Board Appoints William G. Dempsey Independent Director](#)  
*Genetic Engineering News: Nov 13 2008 11:40AM Matching: abbott laboratories*
- [TyRx Pharma, Inc.: TyRx Board Appoints William G. Dempsey Independent Director](#)  
*Market Wire: Nov 13 2008 11:13AM Matching: abbott laboratories*
- [Abbott Laboratories claims market leadership](#)  
*North County Times: Nov 13 2008 7:18AM Matching: abbott laboratories*
- [Abbott Still Expects 4Q FDA Approval For Drug TriLipix - CFO](#)  
*Lloyd's: Nov 13 2008 2:11AM Matching: abbott laboratories*
- [Abbott Still Expects 4Q FDA Approval For Drug TriLipix - CFO \(DJ\)](#)  
*Easy Bourse: Nov 13 2008 1:51AM Matching: abbott laboratories*
- [Abbott Still Expects 4Q FDA Approval For Drug TriLipix - CFO](#)  
*CNN Money: Nov 13 2008 12:17AM Matching: abbott laboratories*
- [Study adds to statin benefits: Abbott stands to gain as cholesterol-fighters cut risk in other heart issue](#)  
*Calibre Macro World: Nov 13 2008 9:59AM Matching: abbott laboratories*
- [Learn about the Global Pharmaceutical Markets](#)  
*Forbes.com: Nov 13 2008 11:37AM Matching: abbott laboratories*
- [Study Adds to Statin Benefits: Abbott Stands to Gain as Cholesterol-fighters Cut Risk in Other Heart Issue](#)  
*Therapeutics Daily: Nov 13 2008 11:58AM Matching: abbott laboratories*
- [Research and Markets: Nanotechnology - World Research and Development Report 2008](#)  
*TMC Net: Nov 13 2008 2:07PM Matching: abbott laboratories*
- [Nanotechnology - World Research and Development Report 2008](#)  
*Forbes.com: Nov 13 2008 11:37AM Matching: abbott laboratories*
- [Abbott's TriLipix Improves Cholesterol Long-term](#)  
*Therapeutics Daily: Nov 12 2008 4:34PM Matching: abbott laboratories*





## Abbott Laboratories Patents:

- 7335678- [Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 \(VR1\) receptor](#)
- 7358263- [Fused bicyclic-substituted amines as histamine-3 receptor ligands](#)
- 7360999- [Means for using single force sensor to supply all necessary information for determination of status of medical pump](#)
- 7364752- [Solid dispersion pharmaceutical formulations](#)
- 7365093- [Endothelin antagonists](#)
- 7365193- [Amino-substituted tricyclic derivatives and methods of use](#)
- 7368552- [Genes involved in polyketide synthase pathways and uses thereof](#)
- 7375126- [Fused compounds that inhibit vanilloid receptor subtype 1 \(VR1\) receptor](#)
- 7375205- [Elongase genes and uses thereof](#)
- 7358251- [N-sulfonylurea apoptosis promoters](#)
- 7357942- [Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens](#)
- 7357851- [Electrochemical cell](#)
- 7345034- [Azacyclosteroid histamine-3 receptor ligands](#)
- 7348343- [Amides useful for treating pain](#)
- 7348346- [Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV \(DPP-IV\)](#)
- 7351586- [Method of making stable calibrators or controls for measuring human natriuretic peptides](#)
- 7351828- [Benzimidazoles that are useful in treating sexual dysfunction](#)
- 7351833- [\(1S,5S\)-3-\(5,6-dichloropyridin-3-yl\)-3,6-diazabicyclo\[3.2.0\]heptane benzenesulfonate](#)
- 7354937- [\(1S,5S\)-3-\(5,6-dichloro-3-pyridinyl\)-3,6-diazabicyclo\[3.2.0\]heptane](#)
- 7354955- [\(2S\)-amino\(phenyl\)acetic acid and derivatives as .alpha..sub.2.delta. voltage-gated calcium channel ligands](#)
- 7377927- [Systems, devices and methods for suturing patient tissue](#)
- 7378105- [Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens](#)
- 7378414- [Anti-infective agents](#)
- 7416556- [Stop-cock suture clamping system](#)
- 7418285- [Analyte test sensor and method of manufacturing the same](#)
- 7422763- [Acid controlled induced viscosity fiber system and uses thereof](#)
- 7423027- [Methods of using gamma cyclodextrin to control blood glucose and insulin secretion](#)
- 7432046- [Methods for the determination of antibody IgG avidity](#)
- 7432245- [Pharmaceutical formulation comprising a peptide angiogenesis inhibitor](#)
- 7432294- [Pharmaceutical formulations](#)
- 7435431- [Method for controlling body weight in estrogen-insufficient women](#)
- 7400979- [Method of identifying inhibitors of Lck](#)
- 7399765- [Substituted diazabicycloalkane derivatives](#)
- 7399480- [Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices](#)
- 7378545- [Crystallization of amino acids using ultrasonic agitation](#)
- 7380654- [Conveyor track drive](#)
- 7389670- [Stent crimping system](#)
- 7390328- [Device and method for suturing of internal puncture sites](#)
- 7390799- [Apoptosis promoters](#)

- 7393659- [Analytical method for the determination of infant formula protein digestibility in vitro](#)
- 7395928- [Child-resistant blister package](#)
- 7396913- [Erythropoietin receptor binding antibodies](#)
- 7435833- [Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

